Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Mulé JJ[au]:

Search results

Items: 1 to 50 of 143

1.

Paradoxical epigenetic regulation of XAF1 mediates plasticity towards adaptive resistance evolution in MGMT-methylated glioblastoma.

Wu Q, Berglund AE, Wang D, MacAulay RJ, Mulé JJ, Etame AB.

Sci Rep. 2019 Oct 1;9(1):14072. doi: 10.1038/s41598-019-50489-2.

2.

STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.

Falahat R, Perez-Villarroel P, Mailloux AW, Zhu G, Pilon-Thomas S, Barber GN, Mulé JJ.

Cancer Immunol Res. 2019 Aug 28. doi: 10.1158/2326-6066.CIR-19-0229. [Epub ahead of print]

PMID:
31462408
3.

OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms.

Zhu G, Brayer J, Padron E, Mulé JJ, Mailloux AW.

Cytometry A. 2018 Oct;93(10):982-986. doi: 10.1002/cyto.a.23598. No abstract available.

4.

Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line.

Zhu G, Nemoto S, Mailloux AW, Perez-Villarroel P, Nakagawa R, Falahat R, Berglund AE, Mulé JJ.

Front Immunol. 2018 Jul 16;9:1609. doi: 10.3389/fimmu.2018.01609. eCollection 2018.

5.

A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression.

Stefanski HE, Jonart L, Goren E, Mulé JJ, Blazar BR.

PLoS One. 2018 Apr 4;13(4):e0193461. doi: 10.1371/journal.pone.0193461. eCollection 2018.

6.

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA.

Front Oncol. 2018 Mar 2;8:44. doi: 10.3389/fonc.2018.00044. eCollection 2018.

7.

Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 May 15;124(10):2254-2255. doi: 10.1002/cncr.31261. Epub 2018 Mar 15. No abstract available.

8.

Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production.

Konno H, Yamauchi S, Berglund A, Putney RM, Mulé JJ, Barber GN.

Oncogene. 2018 Apr;37(15):2037-2051. doi: 10.1038/s41388-017-0120-0. Epub 2018 Jan 25.

9.

Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy.

Yagawa Y, Robertson-Tessi M, Zhou SL, Anderson ARA, Mulé JJ, Mailloux AW.

Sci Rep. 2017 Nov 22;7(1):15996. doi: 10.1038/s41598-017-15924-2.

10.

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 Jan 15;124(2):297-305. doi: 10.1002/cncr.30946. Epub 2017 Oct 12.

11.

Tumour radiosensitivity is associated with immune activation in solid tumours.

Strom T, Harrison LB, Giuliano AR, Schell MJ, Eschrich SA, Berglund A, Fulp W, Thapa R, Coppola D, Kim S, Frakes J, Foekens J, Mulé JJ, Torres-Roca JF.

Eur J Cancer. 2017 Oct;84:304-314. doi: 10.1016/j.ejca.2017.08.001. Epub 2017 Aug 29.

12.

BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats.

Wang D, Berglund AE, Kenchappa RS, MacAulay RJ, Mulé JJ, Etame AB.

Sci Rep. 2017 Aug 24;7(1):9350. doi: 10.1038/s41598-017-09503-8.

13.

Tumor-Associated Tertiary Lymphoid Structures: Gene-Expression Profiling and Their Bioengineering.

Zhu G, Falahat R, Wang K, Mailloux A, Artzi N, Mulé JJ.

Front Immunol. 2017 Jun 30;8:767. doi: 10.3389/fimmu.2017.00767. eCollection 2017.

14.

Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes.

Prabhakaran S, Rizk VT, Ma Z, Cheng CH, Berglund AE, Coppola D, Khalil F, Mulé JJ, Soliman HH.

Breast Cancer Res. 2017 Jun 19;19(1):71. doi: 10.1186/s13058-017-0864-z.

15.

Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.

Strom T, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE, Messina JL, Khushalani NI, Zager JS, Sarnaik A, Mulé JJ, Trotti AM, Eschrich SA, Sondak VK, Harrison LB.

J Natl Compr Canc Netw. 2017 Apr;15(4):473-482.

PMID:
28404758
16.

Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.

Sung H, Kanchi KL, Wang X, Hill KS, Messina JL, Lee JH, Kim Y, Dees ND, Ding L, Teer JK, Yang S, Sarnaik AA, Sondak VK, Mulé JJ, Wilson RK, Weber JS, Kim M.

Oncotarget. 2016 Apr 26;7(17):23885-96. doi: 10.18632/oncotarget.8127.

17.

BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.

Wang D, Berglund A, Kenchappa RS, Forsyth PA, Mulé JJ, Etame AB.

Sci Rep. 2016 Feb 18;6:21710. doi: 10.1038/srep21710.

18.

OMIP-031: Immunologic checkpoint expression on murine effector and memory T-cell subsets.

Nemoto S, Mailloux AW, Kroeger J, Mulé JJ.

Cytometry A. 2016 May;89(5):427-9. doi: 10.1002/cyto.a.22808. Epub 2016 Feb 9. No abstract available.

19.

Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.

Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ.

Cancer Res. 2016 Mar 15;76(6):1381-90. doi: 10.1158/0008-5472.CAN-15-1743. Epub 2015 Dec 30. Erratum in: Cancer Res. 2017 May 1;77(9):2552.

20.

Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response.

Mihm MC Jr, Mulé JJ.

Cancer Immunol Res. 2015 Aug;3(8):827-35. doi: 10.1158/2326-6066.CIR-15-0143. Review.

21.

Cancer immunotherapy meets biomaterials.

Weber JS, Mulé JJ.

Nat Biotechnol. 2015 Jan;33(1):44-5. doi: 10.1038/nbt.3119. No abstract available.

PMID:
25574635
22.

Clonal architectures and driver mutations in metastatic melanomas.

Ding L, Kim M, Kanchi KL, Dees ND, Lu C, Griffith M, Fenstermacher D, Sung H, Miller CA, Goetz B, Wendl MC, Griffith O, Cornelius LA, Linette GP, McMichael JF, Sondak VK, Fields RC, Ley TJ, Mulé JJ, Wilson RK, Weber JS.

PLoS One. 2014 Nov 13;9(11):e111153. doi: 10.1371/journal.pone.0111153. eCollection 2014.

23.

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter.

Radvanyi L, Pilon-Thomas S, Peng W, Sarnaik A, Mulé JJ, Weber J, Hwu P.

Clin Cancer Res. 2013 Oct 1;19(19):5541. doi: 10.1158/1078-0432.CCR-13-1054. Epub 2013 Sep 18. No abstract available.

24.

Examination of MARCO activity on dendritic cell phenotype and function using a gene knockout mouse.

Komine H, Kuhn L, Matsushita N, Mulé JJ, Pilon-Thomas S.

PLoS One. 2013 Jul 1;8(7):e67795. doi: 10.1371/journal.pone.0067795. Print 2013.

25.

12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?

Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ.

Sci Rep. 2012;2:765. doi: 10.1038/srep00765. Epub 2012 Oct 24.

26.

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA.

J Immunother. 2012 Oct;35(8):615-20.

27.

Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling.

Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, Mulé JJ.

Am J Pathol. 2011 Jul;179(1):37-45. doi: 10.1016/j.ajpath.2011.03.007. Epub 2011 May 3.

28.

Chemokines: can effector cells be redirected to the site of the tumor?

Dubinett SM, Lee JM, Sharma S, Mulé JJ.

Cancer J. 2010 Jul-Aug;16(4):325-35. doi: 10.1097/PPO.0b013e3181eb33bc. Review.

29.

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.

Pilon-Thomas S, Mackay A, Vohra N, Mulé JJ.

J Immunol. 2010 Apr 1;184(7):3442-9. doi: 10.4049/jimmunol.0904114. Epub 2010 Mar 1.

30.

Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.

Matsushita N, Komine H, Grolleau-Julius A, Pilon-Thomas S, Mulé JJ.

Cancer Immunol Immunother. 2010 Jun;59(6):875-84. doi: 10.1007/s00262-009-0813-5. Epub 2010 Jan 8.

31.

Dendritic cell-based vaccines for pancreatic cancer and melanoma.

Mulé JJ.

Ann N Y Acad Sci. 2009 Sep;1174:33-40. doi: 10.1111/j.1749-6632.2009.04936.x.

PMID:
19769734
32.

Ectopic lymph nodes within human solid tumors.

Coppola D, Mulé JJ.

J Clin Oncol. 2008 Sep 20;26(27):4369-70. doi: 10.1200/JCO.2008.17.6149. No abstract available.

PMID:
18802146
33.

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.

Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ.

J Immunother. 2008 Jul-Aug;31(6):591-8. doi: 10.1097/CJI.0b013e31817fd90b.

34.

Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.

Koike N, Pilon-Thomas S, Mulé JJ.

J Immunother. 2008 May;31(4):402-12. doi: 10.1097/CJI.0b013e31816cabbb.

PMID:
18391755
35.

Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis.

Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, Liang C, Jung JU, Cheng JQ, Mulé JJ, Pledger WJ, Wang HG.

Nat Cell Biol. 2007 Oct;9(10):1142-51. Epub 2007 Sep 23.

36.

To ablate or not to ablate? HSCs in the T cell driver's seat.

Anasetti C, Mulé JJ.

J Clin Invest. 2007 Feb;117(2):306-10.

37.
38.

Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.

Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mulé JJ, Riker AI.

J Immunother. 2006 Jul-Aug;29(4):381-7.

PMID:
16799333
39.

Allogeneic and autologous melanoma vaccines: where have we been and where are we going?

Sondak VK, Sabel MS, Mulé JJ.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2337s-2341s. Review.

40.

Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.

Pilon-Thomas S, Verhaegen M, Kuhn L, Riker A, Mulé JJ.

Cancer Immunol Immunother. 2006 Oct;55(10):1238-46. Epub 2005 Nov 29.

PMID:
16315029
41.

Dendritic cell-based vaccines for cancer therapy.

Grolleau A, Sloan A, Mulé JJ.

Cancer Treat Res. 2005;123:181-205. Review. No abstract available.

PMID:
16211871
42.

Dendritic cell-based therapeutics for breast cancer.

Pilon-Thomas SA, Verhaegen ME, Mulé JJ.

Breast Dis. 2004;20:65-71. Review.

PMID:
15687708
43.

Translation of cancer immunotherapies.

Mulé JJ, Weber JS.

Nat Med. 2004 Nov;10(11):1153; author reply 1153-4. No abstract available.

PMID:
15516900
44.

Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.

Asavaroengchai W, Kotera Y, Koike N, Pilon-Thomas S, Mulé JJ.

Biol Blood Marrow Transplant. 2004 Aug;10(8):524-33.

45.

Current developments of immunotherapy in the clinic.

Antonia S, Mulé JJ, Weber JS.

Curr Opin Immunol. 2004 Apr;16(2):130-6. Review.

PMID:
15023403
46.

Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector.

Terando A, Roessler B, Mulé JJ.

Cancer Gene Ther. 2004 Mar;11(3):165-73.

PMID:
14726959
47.
48.

On combining antineoplastic drugs with tumor vaccines.

Terando A, Mulé JJ.

Cancer Immunol Immunother. 2003 Nov;52(11):680-5. Epub 2003 Aug 29. Review. No abstract available.

49.

Enhancing dendritic cell-based vaccines by gene modification.

Terando A, Mulé JJ.

Blood Cells Mol Dis. 2003 Jul-Aug;31(1):80-3. Review. No abstract available.

PMID:
12850489
50.

Making room for T cells.

Maine GN, Mulé JJ.

J Clin Invest. 2002 Jul;110(2):157-9. Review. No abstract available.

Supplemental Content

Support Center